rs2268458 — TSHR TSHR Intron 1 Meta-Analysis Variant

Intronic variant in TSHR intron 1; the C allele increases susceptibility to Graves' disease by altering thyroid-stimulating hormone receptor expression in the thymus, impairing central immune tolerance to TSHR — but notably shows no association with Graves' ophthalmopathy, suggesting variant-specific effects within this regulatory locus

See your personal result for TSHR

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

TSHR Intron 1 — A Variant Without Orbital Reach

The thyroid-stimulating hormone receptor is the central target of Graves' disease autoimmunity. Stimulating autoantibodies (TRAbs) against TSHR permanently mimic TSH, overriding the pituitary's feedback control and driving unchecked thyroid hormone production. rs2268458 is an [intronic variant | A variant within a non-coding intron that can influence gene regulation and expression without altering the protein sequence] in the unusually large intron 1 of the TSHR gene — the same region that harbours the better-studied rs12101255 and rs179247 Graves' susceptibility variants. What sets rs2268458 apart within this locus is a notable absence: unlike some TSHR SNPs, this variant shows no statistically significant association with Graves' ophthalmopathy (GO), the orbital complication affecting 25–30% of Graves' patients, suggesting that not all intron 1 variants are regulatory equivalents.

The Mechanism

TSHR intron 1 contains regulatory elements that control tissue-restricted expression of the receptor, including in thymic epithelial cells — where autoreactive T cells are educated and eliminated. Reduced intrathymic TSHR expression, caused by risk variants in this region, means fewer TSHR-presenting cells are available for clonal deletion of autoreactive T cells, allowing TSHR-reactive T cells to escape into the periphery. A landmark 2014 PNAS study by Stefan et al.11 Stefan et al.
Genetic-epigenetic dysregulation of thymic TSH receptor gene expression triggers thyroid autoimmunity established this mechanism for adjacent rs12101255/rs12101261, identifying interferon-alpha-induced PLZF repressor binding as the epigenetic link between viral infection and thyroid autoimmunity.

The precise regulatory role of rs2268458 within this intron 1 region has not been separately characterised at the mechanistic level — Yin et al. 200822 Yin et al. 2008
Influence of the TSH receptor gene on susceptibility to Graves' disease and Graves' ophthalmopathy noted that "direct functional analyses are now needed to help explain the mechanisms of this TSHR gene susceptibility." The variant's distinct phenotypic signature — Graves' disease susceptibility without ophthalmopathy association — implies it tags a regulatory effect at the TSHR locus that diverges from the orbital-disease pathway.

The finding that CC homozygotes face elevated relapse risk after antithyroid drug treatment (Eliana 2017) suggests the C allele may maintain a pro-autoimmune state that persists even after pharmacological thyroid function control — potentially reflecting impaired re-establishment of tolerance once the autoimmune response is triggered.

The Evidence

rs2268458 was identified as the most-associated TSHR SNP in a landmark study by Dechairo et al.33 Dechairo et al.
Association of the TSHR gene with Graves' disease: the first disease-specific locus (2005), analysing 1,059 autoimmune thyroid disease cases and 971 controls. The haplotype containing rs2268458 reached P<1×10⁻⁶ (OR 1.7) in discovery and was independently replicated: GD P=2×10⁻⁶, OR 1.3, in 1,366 cases and 1,061 UK Caucasian controls. No association was found with autoimmune hypothyroidism, establishing this as a Graves'-specific signal.

Yin et al.44 Yin et al.
Influence of the TSH receptor gene on susceptibility to Graves' disease and Graves' ophthalmopathy (2008) replicated the association in 200 female Caucasian GD patients versus 118 controls (OR 1.8, P=0.018 for C-containing genotype), and specifically examined 120 Graves' ophthalmopathy patients: no association with GO was found. The Xiong et al. meta-analysis (4,790 GD cases, 5,350 controls)55 Xiong et al. meta-analysis (4,790 GD cases, 5,350 controls)
Genetic associations of the thyroid stimulating hormone receptor gene with Graves diseases and Graves ophthalmopathy (2016) confirmed that rs2268458 does not distinguish GO patients from GD-without-GO, reinforcing the variant-specific null ophthalmopathy finding.

A clinical study by Eliana et al.66 Eliana et al.
Role of CTLA-4, TSHR and regulatory T-cells as risk factors for relapse in Graves disease (2017) extended rs2268458's clinical relevance: CC homozygotes showed significantly elevated relapse rates 12 months after antithyroid drug cessation (P=0.003) in 144 Indonesian patients, suggesting the CC genotype is not only a disease-onset marker but a treatment-response predictor.

Practical Actions

The C allele elevates Graves' disease susceptibility approximately 1.3–1.8-fold. Because rs2268458 does not predict ophthalmopathy independently, risk management for C allele carriers focuses on Graves' disease itself — early detection, thyroid function surveillance, and reducing modifiable autoimmune triggers.

CC homozygotes face the double burden of elevated disease onset risk and, if Graves' disease develops, elevated relapse risk after antithyroid drug treatment — making upfront awareness of treatment options (radioiodine ablation or thyroidectomy as definitive therapy) particularly relevant when discussing treatment strategy with an endocrinologist.

Selenium at 100–200 mcg/day has RCT evidence for reducing TRAb titres and autoimmune thyroid activity in Graves' patients; because the TSHR intron 1 risk variants appear to lower the immune-tolerance threshold for TSHR, selenium's immunomodulatory effect is a genotype-informed intervention for C allele carriers.

Interactions

rs2268458 maps to TSHR intron 1 alongside rs12101255 (the most-studied Graves' intron 1 SNP, with OR ~1.5–2.2 in meta-analyses) and rs179247. These three variants are in linkage disequilibrium and were co-studied in early TSHR haplotype work; whether rs2268458 contributes independently or purely as a tag for the rs12101255 haplotype block has not been resolved.

Syed et al. 200777 Syed et al. 2007
Preliminary evidence for interaction of PTPN12 polymorphism with TSHR genotype and association with Graves' ophthalmopathy demonstrated statistical interaction between PTPN12 polymorphisms and the TSHR rs2268458 genotype in mild-to-moderate Graves' ophthalmopathy — an intriguing finding given that rs2268458 alone shows no GO association, suggesting the ophthalmopathy signal may emerge only in combination with PTPN12 variants rather than from rs2268458 in isolation.

Beyond the TSHR locus, independent Graves' susceptibility loci include PTPN22 rs2476601 (T-cell activation threshold), CTLA4 rs3087243 and rs231775 (T-cell checkpoint control), and HLA-DRB1 alleles (antigen presentation) — each acting through mechanisms distinct from the thymic TSHR expression pathway.

Genotype Interpretations

What each possible genotype means for this variant.

TT Typical Graves' Risk Normal

Standard TSHR intron 1 genotype — no elevated Graves' disease susceptibility from this variant

You carry two copies of the T allele at rs2268458 — the lower-risk genotype at this TSHR intron 1 locus. Approximately 61% of people globally share this homozygous T genotype (more prevalent in African populations at ~85%). This variant does not contribute elevated Graves' disease susceptibility for you. Other genetic and environmental factors still influence your overall autoimmune thyroid risk, but rs2268458 is not one of them.

CT One Risk Allele Intermediate

One C risk allele — modestly elevated Graves' disease susceptibility

Unlike some TSHR intron 1 variants, rs2268458 does not appear to specifically predict Graves' ophthalmopathy (the orbital complication affecting eyes and vision) — your C allele elevates risk for Graves' disease itself but does not independently indicate elevated eye involvement risk. The codominant pattern means TC carriers occupy an intermediate risk tier, with CC homozygotes carrying higher risk for both disease onset and relapse.

Graves' disease is the most common cause of hyperthyroidism, affecting roughly 1–2% of women and 0.1–0.2% of men. Environmental triggers include viral illness, high iodine intake, smoking, and postpartum immune changes.

CC Two Risk Alleles High Risk

Two C risk alleles — elevated Graves' disease susceptibility and higher relapse risk after treatment

The CC genotype presents a clinically distinct risk profile compared with TC carriers. The relapse association found by Eliana et al. 2017 in 144 patients (P=0.003) suggests that CC homozygotes have a pro-autoimmune thyroid state that persists beyond biochemical euthyroidism achieved with antithyroid drugs such as methimazole or propylthiouracil. This makes upfront awareness of definitive treatment options — radioiodine ablation or thyroidectomy — particularly relevant for CC carriers who are considering antithyroid drug therapy alone.

The variant maps to TSHR intron 1 alongside rs12101255 and rs179247, which together define the major Graves' susceptibility haplotype at this locus. Whether rs2268458 contributes an independent signal or acts as a tag for the same regulatory element has not been fully resolved.

Graves' disease is associated with downstream risks including atrial fibrillation from sustained tachycardia and accelerated bone loss from thyroid hormone excess — two reasons why early diagnosis and definitive treatment matter for CC carriers.